NT PHARMA (01011) expects a net loss of approximately RMB 10.9 million to 15.9 million in the fiscal year 2025.

23:42 30/03/2026

Tai Ling Pharmaceuticals (01011) announced that, following further discussions with the company's auditors during the audit process, and based on the audit work completed by the auditors as of the date of this announcement, the Board hereby further notifies shareholders and potential investors that the Group expects to recognize a one-time non-cash income of approximately HK$15.4 million (equivalent to approximately RMB 14.1 million) in connection with the issuance of new shares to repay debts. As a result, the Group's expected loss for the year ended December 31, 2025, will be further reduced by approximately HK$15.4 million (equivalent to approximately RMB 14.1 million) compared to the previous disclosure, and the revised expected net loss will range from approximately RMB 10.9 million to 15.9 million.

NT Pharma (01011) announced that, following further discussions with the company's auditor during the audit process and based on the auditor's completed audit work as of the date of this announcement, the board of directors hereby notifies shareholders and potential investors that the group expects to recognize a one-time non-cash gain of approximately HK$15.4 million (equivalent to approximately RMB 14.1 million) from the issuance of new shares to settle debt. As a result, the group's expected loss for the year ending December 31, 2025 will be further reduced by approximately HK$15.4 million (equivalent to approximately RMB 14.1 million) compared to what was previously disclosed, and the revised expected net loss will range from approximately RMB 10.9 million to 15.9 million.

RENRUI HR (06919) released its annual performance report, with a net profit attributable to shareholders of 87.55 million yuan, turning a loss into a profit compared to the previous year.

BOAN BIOTECH (06955) announced its annual performance, with a net profit attributable to shareholders of 7.144 million yuan, a year-on-year decrease of 90.24%.

RUNHUA SERVICE (02455) announced its 2025 annual performance, with a net profit attributable to shareholders of RMB 46.32 million, an increase of 1.7% year-on-year.

RENRUI HR (06919) released its annual performance report, with a net profit attributable to shareholders of 87.55 million yuan, turning a loss into a profit compared to the previous year.

BOAN BIOTECH (06955) announced its annual performance, with a net profit attributable to shareholders of 7.144 million yuan, a year-on-year decrease of 90.24%.

RUNHUA SERVICE (02455) announced its 2025 annual performance, with a net profit attributable to shareholders of RMB 46.32 million, an increase of 1.7% year-on-year.